DOI: 10.12890/2024_004767

Pembrolizumab in combination with FOLFIRINOX for treatment of advanced pancreatic adenocarcinoma with MSI-H

Authors

  • Ashmin Singh Internal Medicine, Bayhealth Medical Center, Dover, USA
  • Nairuti Sanghavi Internal Medicine, Bayhealth Medical Center, Dover, USA
  • Vandana Bandari Internal Medicine, Bayhealth Medical Center, Dover, USA
  • Iftekhar Khan Hematology-Oncology, Bayhealth Medical Center, Dover, USA
  • Abeer Alfaraj Hematology-Oncology, Bayhealth Medical Center, Dover, USA

ashmin_singh@bayhealth.org

Keywords

MSI-H, pembrolizumab, pancreatic adenocarcinoma

Abstract

Pancreatic cancer is one of the four most common causes of cancer-related death in the United States. Our patient had metastatic pancreatic cancer with a high tumour burden. He was trialled on an unconventional treatment of combination immunotherapy and chemotherapy. It resulted in decreased cancer burden and decreased FDG activity on a PET scan. Further studies are needed for standard pancreatic cancer treatment.

View the entire article

Downloads

References

  1. Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. Nat Rev Dis Primers 2016;2:16022.
  2. Balaban EP, Mangu PB, Yee NS. Locally advanced unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract 2017;13:265–269.
  3. National Comprehensive Cancer Network. Pancreatic adenocarcinoma (Version 2.2024 — April 30, 2024). https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455
  4. Foley K, Kim V, Jaffee E, Zheng L. Current progress in immunotherapy for pancreatic cancer. Cancer Lett 2016;381:244–251.
  5. Zhao L, Singh V, Ricca A, Lee P. Survival benefit of pembrolizumab for patients with pancreatic adenocarcinoma: a case series. J Med Cases 2022;13:240–243.

Published

2024-09-24

Issue

Vol. 11 No. 10 (2024)

Categories

How to Cite

1.
Singh A, Sanghavi N, Bandari V, Khan I, Alfaraj A. Pembrolizumab in combination with FOLFIRINOX for treatment of advanced pancreatic adenocarcinoma with MSI-H. EJCRIM [Internet]. 2024 Sep. 24 [cited 2026 Nov. 4];11(10). Available from: https://ejcrim.com/index.php/ejcrim/article/view/4767

Most read articles by the same author(s)